Physician profile
Mir O Ali
NPI 1083800965
$147,247.85
in general payments reported to CMS, 2019-2025
30 companies · $849 in 2025
The $849 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $39K · 2021: $39K · 2022: $17K · 2023: $15K · 2024: $2,080 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $1,628 · Travel and Lodging: $1,560 · Education: $42.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $14,732.50 |
| Food and Beverage | $1,628.01 |
| Travel and Lodging | $1,560.00 |
| Education | $42.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $70,554.04 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mylan Specialty L.P. | $48,279.26 | 2019-2024 | Yupelri, Yupelri |
| Astrazeneca Pharmaceuticals LP | $17,776.83 | 2019-2025 | Breztri |
| Sunovion Pharmaceuticals INC. | $7,038.34 | 2019-2021 | |
| Viiv Healthcare Company | $1,600.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.70 | 2019-2025 | Ofev |
| Actelion Pharmaceuticals US, INC. | $247.42 | 2019-2022 | |
| United Therapeutics Corporation | $225.50 | 2020-2024 | Tyvaso, Orenitram |
| Jazz Pharmaceuticals INC. | $207.01 | 2021-2025 | |
| Harmony Biosciences LLC | $142.39 | 2025 | |
| Genentech USA, INC. | $135.92 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $82.46 | 2024-2025 | Dupixent |
| Verona Pharma, INC. | $68.51 | 2025 | Ohtuvayre |
| Advanced Respiratory, INC | $67.52 | 2019-2020 | |
| Baxter Healthcare | $67.08 | 2022-2023 | Hillrom - Life 2000 Ventilation System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $59.25 | 2023-2024 | Nuzyra |
| Insmed, INC. | $55.95 | 2024-2025 | Arikayce |
| Philips North America LLC | $53.01 | 2019 | |
| Electromed, INC. | $48.48 | 2025 | Smartvest |
| Grifols USA, LLC | $37.52 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.98 | 2022 | |
| Novo Nordisk INC | $33.86 | 2023-2024 | Wegovy, Saxenda |
| Mallinckrodt Hospital Products INC. | $30.13 | 2023 | Acthar |
| Ani Pharmaceuticals, INC. | $28.49 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $23.17 | 2019 | |
| Avadel Cns Pharmaceuticals, LLC | $22.37 | 2025 | Lumryz |
| Viatris Specialty LLC | $21.87 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $21.28 | 2025 | Winrevair |
| Novartis Pharmaceuticals Corporation | $13.53 | 2019 | |
| Gilead Sciences, INC. | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mir Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.